CTOs on the Move

Lee Pharmaceuticals

www.leepharmaceuticals.com

 
Lee Pharmaceuticals is an established manufacturer of quality lip balm, saline nasal spray and OTC products. We are aggressively pursuing the Private Label Lip Balm and OTC business with our products that are national brand equivalent.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

VaxInnate Corporation

VaxInnate Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cranbury, NJ. To find more information about VaxInnate Corporation, please visit www.vaxinnate.com

TVG-Medulla

TVG-Medulla, LLC (Medulla) is a wellness-focused healthcare management organization providing incomparable support and services to more than 40 Chiro One Wellness Center locations. In addition to our full-scale management departments and a wide-range of Medulla career opportunities, Medulla also offers engaging wellness programs and education services to communities, employers and organizations across Chicagoland.

MakroCare

MakroCare is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Alternatives

Care Alternatives is a Cranford, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.